FLI1 and sarcoma: According Baldauf et al. 2018, EWSR1-NFATC2-positive sarcomas are transcriptionally distinct from tumors with EWSR1-FLI1 translocation and should be treated as an entity distinct from EWSR1-ETS tumors [67].